Monoclonal Antibody Disposition: a Simplified PBPK Model and Its Implications for the Derivation and Interpretation of Classical Compartment Models

Overview

Journal J Pharmacokinet Pharmacodyn

Publisher Springer

Specialty Pharmacology

Date 2014 Feb 5

PMID 24493102

Citations 26

Authors

Ludivine Fronton

Sabine Pilari

Wilhelm Huisinga

Affiliations

Soon will be listed here.

Abstract

The structure, interpretation and parameterization of classical compartment models as well as physiologically-based pharmacokinetic (PBPK) models for monoclonal antibody (mAb) disposition are very diverse, with no apparent consensus. In addition, there is a remarkable discrepancy between the simplicity of experimental plasma and tissue profiles and the complexity of published PBPK models. We present a simplified PBPK model based on an extravasation rate-limited tissue model with elimination potentially occurring from various tissues and plasma. Based on model reduction (lumping), we derive several classical compartment model structures that are consistent with the simplified PBPK model and experimental data. We show that a common interpretation of classical two-compartment models for mAb disposition-identifying the central compartment with the total plasma volume and the peripheral compartment with the interstitial space (or part of it)-is not consistent with current knowledge. Results are illustrated for the monoclonal antibodies 7E3 and T84.66 in mice.

Citing Articles

Investigation of simplified physiologically-based pharmacokinetic models in rat and human.

Yau E, Olivares-Morales A, Ogungbenro K, Aarons L, Gertz M CPT Pharmacometrics Syst Pharmacol. 2023; 12(3):333-345.

PMID: 36754967 PMC: 10014059. DOI: 10.1002/psp4.12911.

Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.

Pasquiers B, Benamara S, Felices M, Nguyen L, Decleves X Int J Mol Sci. 2022; 23(21).

PMID: 36361546 PMC: 9657028. DOI: 10.3390/ijms232112754.

Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.

Sanchez J, Nicolini V, Fahrni L, Waldhauer I, Walz A, Jamois C AAPS J. 2022; 24(6):106.

PMID: 36207642 DOI: 10.1208/s12248-022-00755-5.

Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.

Van De Vyver A, Walz A, Heins M, Abdolzade-Bavil A, Kraft T, Waldhauer I Front Pharmacol. 2022; 13:958543.

PMID: 36105215 PMC: 9465605. DOI: 10.3389/fphar.2022.958543.

Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment.

Capuani S, Hernandez N, Paez-Mayorga J, Dogra P, Wang Z, Cristini V Mater Today Bio. 2022; 16:100390.

PMID: 36033374 PMC: 9403502. DOI: 10.1016/j.mtbio.2022.100390.

References

Krippendorff B, Kuester K, Kloft C, Huisinga W . Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn. 2009; 36(3):239-60. PMC: 2718226. DOI: 10.1007/s10928-009-9120-1. View

Kawai R, Lemaire M, Steimer J, Bruelisauer A, NIEDERBERGER W, Rowland M . Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm. 1994; 22(5):327-65. DOI: 10.1007/BF02353860. View

Dirks N, Nolting A, Kovar A, Meibohm B . Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008; 48(3):267-78. DOI: 10.1177/0091270007313393. View

Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10(7):1093-5. DOI: 10.1023/a:1018943613122. View

Huisinga W, Solms A, Fronton L, Pilari S . Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst Pharmacol. 2013; 1:e4. PMC: 3603474. DOI: 10.1038/psp.2012.3. View

Ferl G, Wu A, DiStefano 3rd J . A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005; 33(11):1640-52. DOI: 10.1007/s10439-005-7410-3. View

Cao Y, Balthasar J, Jusko W . Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013; 40(5):597-607. PMC: 3836053. DOI: 10.1007/s10928-013-9332-2. View

Vugmeyster Y, Xu X, Theil F, Khawli L, Leach M . Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem. 2012; 3(4):73-92. PMC: 3342576. DOI: 10.4331/wjbc.v3.i4.73. View

Stoop J, Zegers B, Sander P, Ballieux R . Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol. 1969; 4(1):101-12. PMC: 1579064. View

10.

Shah D, Betts A . Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2011; 39(1):67-86. DOI: 10.1007/s10928-011-9232-2. View

11.

Lammerts van Bueren J, Bleeker W, Bogh H, Houtkamp M, Schuurman J, van de Winkel J . Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006; 66(15):7630-8. DOI: 10.1158/0008-5472.CAN-05-4010. View

12.

Grimm H . Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. 2009; 36(5):407-20. DOI: 10.1007/s10928-009-9129-5. View

13.

Garg A, Balthasar J . Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007; 34(5):687-709. DOI: 10.1007/s10928-007-9065-1. View

14.

Rodgers T, Leahy D, Rowland M . Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005; 94(6):1259-76. DOI: 10.1002/jps.20322. View

15.

Mager D, Krzyzanski W . Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005; 22(10):1589-96. DOI: 10.1007/s11095-005-6650-0. View

16.

Jones H, Mayawala K, Poulin P . Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 2012; 15(2):377-87. PMC: 3675752. DOI: 10.1208/s12248-012-9446-2. View

17.

Urva S, Yang V, Balthasar J . Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2009; 99(3):1582-600. DOI: 10.1002/jps.21918. View

18.

Hansen R, Balthasar J . Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003; 92(6):1206-15. DOI: 10.1002/jps.10364. View

19.

Wiczling P, Rosenzweig M, Vaickus L, Jusko W . Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol. 2009; 50(5):494-506. DOI: 10.1177/0091270009349376. View

20.

Borvak J, Richardson J, MEDESAN C, Antohe F, Radu C, Simionescu M . Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998; 10(9):1289-98. DOI: 10.1093/intimm/10.9.1289. View